血清miRNA作为生物标志物诊断阿尔茨海默病

发布时间：2018-03-15 07:27

本文选题：阿尔茨海默病　切入点：血清microRNA　出处：《南京大学》2012年硕士论文　论文类型：学位论文

【摘要】：目的阿尔茨海默病(Alzheimer's disease, AD)作为一种最常见的痴呆症,它正在困扰着全世界成千上万的人。早期诊断阿尔茨海默病对于延缓疾病的发展和提高病人的生活质量非常关键。目前,因为缺乏特异性和敏感性高的生物标志物,该病的监测,特别是在早期监测仍然存在很大的挑战。最近由我们实验组和其他科研单位研究发现,人类的血清里面含有大量的微小核糖核酸(microRNA),并且这些微小核糖核酸的表达谱可以用来诊断各种类型的疾病,包括癌症。本研究中,首先发现血清microRNA表达谱可以用于诊断阿尔茨海默病。方法我们共收集了112个病人和108个对照组病人的血清样本。首先用Solexa测序技术在全基因组范围内分析了阿尔茨海默病病人和对照组的血清微小核糖核酸表达谱。然后在单个血清样本中用实时荧光定量PCR技术验证从Solexa测序技术中选出来的差异表达的miRNA。结果Solexa测序结果表明,相对于对照组来说,阿尔茨海默病病人血清中有9个miRNA表达显著上升,并且有23个miRNA的表达显著下降。实时荧光定量PCR实验结果表明miR-31, miR-93, miR-143, miR-146a这四个miRNA的表达谱可以作为诊断阿尔茨海默病的生物标志物。受试者操作曲线(ROC)下面积分布从0.622到0.657不等。另外,miR-93的表达在轻度认知伤害病人(MCI)和对照组中有差异。niR-31, miR-93和miR-146a这组miRNA可以区分阿尔茨海默病病人和血管性痴呆病人。结论我们找到了一组血清nicroRNA (miR-31, miR-93, miR-143, miR-146a)可以作为一种新型的,无创伤性的生物标志物用来诊断阿尔茨海默病。
[Abstract]:Objective Alzheimer's disease (ADD), one of the most common forms of dementia, is affecting thousands of people around the world. Early diagnosis of Alzheimer's disease is critical to slow down the development of the disease and improve the quality of life of patients. Because of the lack of specific and sensitive biomarkers, surveillance of the disease, especially early surveillance, remains a challenge. Human serum contains a large number of microRNAs of ribonucleic acid, and these microRNA expression profiles can be used to diagnose various types of diseases, including cancer. First, we found that serum microRNA expression profile can be used in the diagnosis of Alzheimer's disease. Methods Serum samples of 112 patients and 108 controls were collected. Serum microRNA expression profiles of Alzheimer's disease patients and controls were analyzed by Solexa sequencing technique. Then the differential expression of miRNA selected from Solexa sequencing technique was verified by real-time fluorescence quantitative PCR in a single serum sample. Results the results of Solexa sequencing showed that the expression of 9 miRNA in serum of Alzheimer's disease patients was significantly increased compared with the control group. The expression of miR-31, miR-93, miR-143 and miR-146a could be used as biomarkers for diagnosis of Alzheimer's disease. The expression of miR-93 in patients with mild cognitive injury (MCI) was different from that in the control group. MiR-93 and miR-146a groups of miRNA could distinguish Alzheimer's disease patients from vascular dementia patients. Conclusion A group of serum nicroRNA miR-31, miR-93, miR-143, miR-146a can be used as a new, non-traumatic biomarker for the diagnosis of Alzheimer's disease.
【学位授予单位】：南京大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R749.16

【共引文献】